The healthspan shelf, two ends of the chain.
Longevity and cellular optimization encompass a broad clinical spectrum. Our formulary features two foundational medications operating at distinct cellular levels: NAD+, the essential coenzyme driving mitochondrial energetics, DNA repair, and cellular redox balance.
Telomeres at one end, mitochondria at the other.
Therapeutic anti-aging medicine targets multiple distinct biological pathways: telomere preservation, sirtuin activation, mitochondrial biogenesis, and cellular cleanup. Addressing long-term cellular health requires specific, targeted interventions for each mechanism.
NAD+ is an essential coenzyme required for cellular energy production, mitochondrial biogenesis, and sirtuin enzyme activation. While not a peptide, direct subcutaneous administration provides superior bioavailability compared to oral precursors (like NMN or NR), supporting optimal systemic NAD+ levels, cognitive clarity, and cellular repair.
Below: Explore the individual formulations, complementary medical treatments, and a decision matrix to assist your practice in selecting the optimal anti-aging care plan.
Three questions, one starting medication.
Supporting mitochondrial biogenesis?
NAD+ sits at the core of sirtuin activation and mitochondrial ATP generation. Direct subcutaneous administration delivers superior bioavailability compared to oral precursors, providing optimal support for cellular energy, metabolic health, and cognitive function.
Pick → NAD+
Targeting broad-spectrum healthspan?
NAD+ operate through distinct, non-overlapping biological pathways, clinicians frequently layer them into comprehensive anti-aging care plans. Multi-axis treatments can also integrate to address systemic recovery alongside cellular energetics.
Pick → NAD+
Patient questions, answered.
Six things we get asked most about the longevity lane. For dosing math, use the calculator. For purity records, every PDP has the full COA archive.
Why subcutaneous NAD+ instead of oral NMN or NR?
Subcutaneous NAD+ bypasses the gut conversion step and reaches systemic circulation directly. Bioavailability is meaningfully higher than oral precursors. Both routes have published research support; choose to match your reference literature.
Is NAD+ a peptide?
No — it's a dinucleotide cofactor. It sits in the longevity lane because the research overlap with peptide longevity work is dense (sirtuins, mitochondrial biogenesis), but mechanistically it's a different class of molecule.
What's the typical longevity medication length?
Telomere-endpoint medication read out over 6–12 months. Mitochondrial endpoints are faster — 4–12 weeks. Plan accordingly. We don't make recommendations.